Veracyte, Inc. (VCYT) stock forecast and price target
Price $24.33 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($24.33)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $1.94 | +9.2% | $591M |
| Next fiscal year ends December 31, 2027 | $1.57 | −19.4% | $634M |
| Next quarter ends December 31, 2026 | $0.38 | −27.7% | $150M |
| Quarter after ends March 31, 2027 | $0.33 | −35.9% | $148M |
Consensus of the analysts covering Veracyte, updated daily. In the last 30 days 2 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 83.3% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Veracyte’s intrinsic value about 41% below today’s market value, and it scores 2.6 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Veracyte stock price target?
The average 12-month target from 10 analysts is $44.60, 83.3% above the current price of $24.33 Targets range from $30.00 to $65.00.
Is Veracyte a buy according to analysts?
The consensus rating is “Buy” (2 strong buy, 7 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Veracyte expected to earn?
Analysts expect EPS of $1.94 for the fiscal year ending December 31, 2026 and $1.57 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.